SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease

Abstract

Abstract Diabetic kidney disease (DKD) remains the leading cause of chronic kidney disease (CKD) worldwide. The pathogenesis of DKD is influenced by functional, histopathological, and immune mechanisms, including NLRP3 inflammasome activity and oxidative stress. The sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown metabolic benefits and the ability to slow the progression of DKD in several clinical studies over the years. Recent studies suggest that the antidiabetic activity also extends to inhibition of the inflammatory response, including modulation of the NLRP3 inflammasome, reduction of pro-inflammatory markers and reduction of oxidative stress. Here we review the efficacy of SGLT2i in the treatment of CKD and discuss the role of the inflammatory response in the development of DKD, including its relationship to the NLRP3 inflammasome and oxidative stress.

Keywords

• Diabetic Nephropathies
• Inflammatory Response
• NLR Family
• Pyrin Domain-Containing 3 Protein
• Inflammasome
• Sodium-Glucose Transporter-2 Inhibitors
• Renal Insufficiency
• Chronic